EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Sold by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD decreased its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 13.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,144,747 shares of the company's stock after selling 347,466 shares during the period. Price T Rowe Associates Inc. MD owned approximately 3.14% of EyePoint Pharmaceuticals worth $15,980,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. Silverarc Capital Management LLC increased its holdings in shares of EyePoint Pharmaceuticals by 21.3% in the fourth quarter. Silverarc Capital Management LLC now owns 121,274 shares of the company's stock valued at $903,000 after purchasing an additional 21,274 shares during the last quarter. Hsbc Holdings PLC grew its holdings in EyePoint Pharmaceuticals by 1.4% in the 4th quarter. Hsbc Holdings PLC now owns 257,615 shares of the company's stock valued at $1,918,000 after buying an additional 3,629 shares in the last quarter. MetLife Investment Management LLC increased its stake in shares of EyePoint Pharmaceuticals by 38.3% in the 4th quarter. MetLife Investment Management LLC now owns 40,502 shares of the company's stock worth $302,000 after acquiring an additional 11,217 shares during the last quarter. MYDA Advisors LLC raised its holdings in shares of EyePoint Pharmaceuticals by 23.3% during the 4th quarter. MYDA Advisors LLC now owns 160,000 shares of the company's stock worth $1,192,000 after acquiring an additional 30,200 shares during the period. Finally, Canada Pension Plan Investment Board boosted its position in shares of EyePoint Pharmaceuticals by 111.3% during the 4th quarter. Canada Pension Plan Investment Board now owns 50,700 shares of the company's stock valued at $378,000 after acquiring an additional 26,700 shares during the last quarter. 99.41% of the stock is owned by hedge funds and other institutional investors.

EyePoint Pharmaceuticals Trading Down 6.0 %

EyePoint Pharmaceuticals stock traded down $0.44 during midday trading on Monday, reaching $6.86. 460,264 shares of the stock traded hands, compared to its average volume of 877,880. The firm has a market cap of $472.04 million, a PE ratio of -3.43 and a beta of 1.39. The company has a 50-day simple moving average of $6.00 and a two-hundred day simple moving average of $7.63. EyePoint Pharmaceuticals, Inc. has a 12-month low of $3.91 and a 12-month high of $14.00.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. The business had revenue of $11.60 million during the quarter, compared to analyst estimates of $11.02 million. Equities research analysts anticipate that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. StockNews.com upgraded shares of EyePoint Pharmaceuticals to a "sell" rating in a report on Friday, March 14th. Citigroup started coverage on EyePoint Pharmaceuticals in a report on Tuesday, January 7th. They issued a "buy" rating and a $33.00 price objective on the stock. Chardan Capital reissued a "buy" rating and set a $33.00 target price on shares of EyePoint Pharmaceuticals in a research note on Thursday, March 6th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $22.00 price target on shares of EyePoint Pharmaceuticals in a research note on Thursday, March 6th. One analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $26.63.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.